Physician profile
Robert Dean Hoffman
NPI 1679561021
$4,083.82
in general payments reported to CMS, 2019-2025
25 companies · $968 in 2025
The $968 reported for 2025 was more than what 79% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $326 · 2021: $142 · 2022: $569 · 2023: $647 · 2024: $744 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,325.63 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $828.91 | 2019-2025 | |
| Glaxosmithkline, LLC. | $417.21 | 2022-2025 | Nucala |
| Stryker Corporation | $378.19 | 2019-2022 | |
| Acclarent, INC | $373.29 | 2019-2023 | Relieva Spinplus, Trudi Nav Cable |
| Aerin Medical INC. | $356.77 | 2019-2025 | |
| Medtronic, INC. | $221.96 | 2023-2025 | Propel |
| Regeneron Healthcare Solutions, INC. | $212.99 | 2019-2025 | Dupixent |
| Hologic Sales and Service, LLC | $171.45 | 2023-2024 | Coolseal Generator |
| Neurent Medical Limited | $164.43 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Hill Dermaceuticals, INC. | $155.09 | 2022 | |
| Genzyme Corporation | $136.43 | 2019-2025 | |
| Intersect Ent, INC. | $125.76 | 2021 | |
| Hikma Pharmaceuticals USA | $84.77 | 2023-2024 | Ryaltris |
| Olympus America INC. | $82.68 | 2019 | |
| Arbor Pharmaceuticals, INC. | $77.47 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $63.13 | 2023-2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $42.84 | 2025 | Tezspire |
| Amgen INC. | $34.00 | 2025 | |
| Lilly USA, LLC | $28.28 | 2025 | Zepbound |
| Medtronic USA, INC. | $25.78 | 2019 | |
| Coopersurgical, INC. | $23.27 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $23.07 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $20.90 | 2023 | |
| Novartis Pharmaceuticals Corporation | $19.67 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.48 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.